A previously published study of antiretroviral pharmacokinetics in the female genital tract of HIV-infected women demonstrated differing degrees of female genital tract penetration among antiretrovirals. These blood plasma (BP) and cervicovaginal fluid (CVF) data were co-modelled for four antiretrovirals with varying CVF exposures
Background: Oral and vaginal preparations of tenofovir as pre-exposure prophylaxis (PrEP) for human ...
Defining tissue and plasma-specific prophylactic drug concentrations is central to pre-exposure prop...
The objective of the study was to measure antiretroviral exposures in four physiological compartment...
A previously published study of antiretroviral pharmacokinetics in the female genital tract of HIV-i...
To describe first dose and steady state antiretroviral drug exposure in the female genital tract
ABSTRACT We report darunavir, ritonavir, and etravirine pharmacokinetics in cervicovaginal fluid and...
This study describes first dose and steady state pharmacokinetics of raltegravir (RAL) in cervicovag...
Antiretrovirals (ARV) that achieve adequate concentrations in anatomical sites of transmission are o...
The exposure of oral antiretroviral (ARV) drugs in the female genital tract (FGT) is variable and al...
To compare single- and multiple-dose maraviroc exposures in cervicovaginal fluid (CVF) and vaginal t...
We did a parallel, three-group, pharmacokinetic evaluation at HIV clinics in Asia (two sites), South...
The efficacy of HIV pre-exposure prophylaxis (PrEP) relies on adherence and may also depend on the r...
Background: To characterize their potential use in pre-exposure prophylaxis (PrEP) we compared the p...
BACKGROUND: Oral and vaginal preparations of tenofovir as pre-exposure prophylaxis (PrEP) for human ...
The incidence of HIV remains alarmingly high in many parts of the world. Prophylactic use of antiret...
Background: Oral and vaginal preparations of tenofovir as pre-exposure prophylaxis (PrEP) for human ...
Defining tissue and plasma-specific prophylactic drug concentrations is central to pre-exposure prop...
The objective of the study was to measure antiretroviral exposures in four physiological compartment...
A previously published study of antiretroviral pharmacokinetics in the female genital tract of HIV-i...
To describe first dose and steady state antiretroviral drug exposure in the female genital tract
ABSTRACT We report darunavir, ritonavir, and etravirine pharmacokinetics in cervicovaginal fluid and...
This study describes first dose and steady state pharmacokinetics of raltegravir (RAL) in cervicovag...
Antiretrovirals (ARV) that achieve adequate concentrations in anatomical sites of transmission are o...
The exposure of oral antiretroviral (ARV) drugs in the female genital tract (FGT) is variable and al...
To compare single- and multiple-dose maraviroc exposures in cervicovaginal fluid (CVF) and vaginal t...
We did a parallel, three-group, pharmacokinetic evaluation at HIV clinics in Asia (two sites), South...
The efficacy of HIV pre-exposure prophylaxis (PrEP) relies on adherence and may also depend on the r...
Background: To characterize their potential use in pre-exposure prophylaxis (PrEP) we compared the p...
BACKGROUND: Oral and vaginal preparations of tenofovir as pre-exposure prophylaxis (PrEP) for human ...
The incidence of HIV remains alarmingly high in many parts of the world. Prophylactic use of antiret...
Background: Oral and vaginal preparations of tenofovir as pre-exposure prophylaxis (PrEP) for human ...
Defining tissue and plasma-specific prophylactic drug concentrations is central to pre-exposure prop...
The objective of the study was to measure antiretroviral exposures in four physiological compartment...